Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug ...

Evotec and Novo Nordisk launched LAB eN² in September 2023 to nurture early research from academic institutions into novel therapeutics.

Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General ...

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing ...

Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects ...

(IN BRIEF) Evotec and Novo Nordisk’s LAB eN² program, a translational drug discovery accelerator, has selected its first three academic research projects focused on addressing cardiometabolic diseases ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to ...

Danish drug maker Novo Nordisk said on Thursday it will reduce the U.S. list prices of two insulin products by more than 70% ...

Catalent (CTLT) stock rises on reports of imminent $16.5 billion sale to Novo Holdings with FTC approval and EU Commission ...

After slashing the U.S. prices of several of its insulin products by 75% at the start of 2024, Novo Nordisk is ending the year by announcing similar price reductions for most of its other insulins ...